ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0819

A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort

Mohamed Tageldin1, Malavikalakshmi Attur2, Nicole Wilson1, Rebecca Schorr3 and Tarun Sharma1, 1Allegheny Health Network, Pittsburgh, PA, 2Drexel University School of Medicine, Philadelphia, PA, 3Highmark Health, Pittsburgh, PA

Meeting: ACR Convergence 2021

Keywords: biologic, Disease-Modifying Antirheumatic Drugs (Dmards), prospective, rheumatoid arthritis, tapering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Patients with chronic RA remain interested in the question of medication tapering per our previous survey-based study within the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) cohort. Few RCTs and retrospective studies have systematically studied clinical outcomes of medication tapering in RA. In this study, we prospectively compared the clinical outcomes of different medication tapering groups within the RHEUMTAP cohort.

Methods: RHEUMTAP is a 2 year prospective cohort of patients with RA in sustained remission on biologics seen at Allegheny Health Network Rheumatology between 11/30/2018 and 11/30/2020 with at least 6 months follow up. Biologic tapering regimens were pre-determined based on provider consensus. Manual electronic health record (EHR) review was performed to confirm sustained remission on biologic therapy defined as CDAI<2.8, stable RA medication use, and absence of flares for a period of at least 6 months. Taper meant a reduction in biologic and/or csDMARD dose, frequency, or discontinuation. Primary outcome was proportion of flares at the end of study period, and secondary outcome was time to flare. Flare was defined as provider diagnosed worsening RA requiring initiation, change or increase in therapy. The 4 groups of comparison were: no taper, only biologic tapered, only csDMARD tapered, and both biologic and csDMARD tapered. Statistical analyses were completed using SAS Enterprise Guide 7.15 HF3 (SAS Institute, Inc, Cary, NC). Multivariable logistic regression analyses were used to estimate adjusted odds of flare. Kaplan Meier survival plots were created to determine the time to flare utilizing the log-rank test to determine significance.

Results: The RHEUMTAP cohort included 346 patients of which 131 patients were confirmed to have sustained remission on biologics +/- csDMARDs based on manual EHR review. Of these 131 patients, 54 patients underwent a medication taper. Flare was experienced by 20 (15%) patients during follow up period, of which 16 were in the taper groups and 4 in the no-taper group. There were no significant differences in characteristics between the groups (table 1). The most frequently tapered biologics were etanercept and adalimumab, and most frequent csDMARD tapered was methotrexate. Patients undergoing any taper (all groups combined) overall were 7.6 times more likely to experience a flare in the follow-up period compared to those not tapered (OR 7.68, 95% CI 2.4-24, p=0.0006). The both biologic and csDMARD tapered group was more likely to experience a flare (OR 26.93, 95% CI 2.5- 276, p< 0.048) and have a shorter time to flare (HR 10.89, SE 0.91, p=0.008) compared to the no-taper group (table 2).

Conclusion: RHEUMTAP is the first real-world prospective cohort study to report the outcomes of different medication tapering groups in RA in sustained remission. In our cohort, patients who tapered both biologics and csDMARDs were more likely to experience a flare and have a shorter time to flare. Larger studies are required to confirm our findings given our wide confidence intervals.

Table 1: Characteristics of Tapered and Not-Tapered groups

Table 2: Primary and secondary outcome (multivariable analyses)

Figure 1: KM survival curve, without flare


Disclosures: M. Tageldin, None; M. Attur, None; N. Wilson, None; R. Schorr, None; T. Sharma, None.

To cite this abstract in AMA style:

Tageldin M, Attur M, Wilson N, Schorr R, Sharma T. A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-real-world-2-year-prospective-study-of-medication-tapering-in-patients-with-ra-in-sustained-remission-in-the-rheumatoid-arthritis-medication-tapering-rheumtap-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-real-world-2-year-prospective-study-of-medication-tapering-in-patients-with-ra-in-sustained-remission-in-the-rheumatoid-arthritis-medication-tapering-rheumtap-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology